Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasisEli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, Share XLilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in psoriasishttps://pharmaphorum.com/news/lillys-mirikizumab-tops-novartis-blockbuster-cosentyx-in-psoriasis/